What is driving interest in Maze Therapeutics right now? Maze Therapeutics (MAZE) has drawn fresh attention after recent trading, with the stock closing at $46.01 and showing mixed short term moves, ...
Maze Therapeutics' Senior Vice President of Finance sold shares towards the end of January 2026, all while the company's stock had one of the best first-year performances of a biopharmaceutical ...
Monday - Friday, 2:00 - 3:00 PM ET In this article Maze Therapeutics has had a great run since its initial public offering in January — and CEO Jason Coloma is hoping that momentum continues as the ...
Human genetics biotech Maze Therapeutics has navigated the biotech world’s tricky fundraising landscape to land a $115 million series D. The round was co-led by investors Frazier Life Sciences and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results